Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 26;10(10):CD013091.
doi: 10.1002/14651858.CD013091.pub2.

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review

Emma C Atakpa  1 , Mangesh A Thorat  1   2   3 , Jack Cuzick  1 , Adam R Brentnall  1
Affiliations

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review

Emma C Atakpa et al. Cochrane Database Syst Rev. .

Abstract

Background: Endocrine therapy is effective at preventing or treating breast cancer. Some forms of endocrine therapy have been shown to reduce mammographic density. Reduced mammographic density for women receiving endocrine therapy could be used to estimate the chance of breast cancer returning or developing breast cancer in the first instance (a prognostic biomarker). In addition, changes in mammographic density might be able to predict how well a woman responds to endocrine therapy (a predictive biomarker). The role of breast density as a prognostic or predictive biomarker could help improve the management of breast cancer.

Objectives: To assess the evidence that a reduction in mammographic density following endocrine therapy for breast cancer prevention in women without previous breast cancer, or for treatment in women with early-stage hormone receptor-positive breast cancer, is a prognostic or predictive biomarker.

Search methods: We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL, MEDLINE, Embase, and two trials registers on 3 August 2020 along with reference checking, bibliographic searching, and contact with study authors to obtain further data.

Selection criteria: We included randomised, cohort and case-control studies of adult women with or without breast cancer receiving endocrine therapy. Endocrine therapy agents included were selective oestrogen receptor modulators and aromatase inhibitors. We required breast density before start of endocrine therapy and at follow-up. We included studies published in English.

Data collection and analysis: We used standard methodological procedures expected by Cochrane. Two review authors independently extracted data and assessed risk of bias using adapted Quality in Prognostic Studies (QUIPS) and Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tools. We used the GRADE approach to evaluate the certainty of the evidence. We did not perform a quantitative meta-analysis due to substantial heterogeneity across studies.

Main results: Eight studies met our inclusion criteria, of which seven provided data on outcomes listed in the protocol (5786 women). There was substantial heterogeneity across studies in design, sample size (349 to 1066 women), participant characteristics, follow-up (5 to 14 years), and endocrine therapy agent. There were five breast density measures and six density change definitions. All studies had at least one domain as at moderate or high risk of bias. Common concerns were whether the study sample reflected the review target population, and likely post hoc definitions of breast density change. Most studies on prognosis for women receiving endocrine therapy reported a reduced risk associated with breast density reduction. Across endpoints, settings, and agents, risk ratio point estimates (most likely value) were between 0.1 and 1.5, but with substantial uncertainty. There was greatest consistency in the direction and magnitude of the effect for tamoxifen (across endpoints and settings, risk ratio point estimates were between 0.3 and 0.7). The findings are summarised as follows. Prognostic biomarker findings: Treatment Breast cancer mortality Two studies of 823 women on tamoxifen (172 breast cancer deaths) reported risk ratio point estimates of ~0.4 and ~0.5 associated with a density reduction. The certainty of the evidence was low. Recurrence Two studies of 1956 women on tamoxifen reported risk ratio point estimates of ~0.4 and ~0.7 associated with a density reduction. There was risk of bias in methodology for design and analysis of the studies and considerable uncertainty over the size of the effect. One study of 175 women receiving an aromatase inhibitor reported a risk ratio point estimate of ~0.1 associated with a density reduction. There was considerable uncertainty about the effect size and a moderate or high risk of bias in all domains. One study of 284 women receiving exemestane or tamoxifen as part of a randomised controlled trial reported risk ratio point estimates of ~1.5 (loco-regional recurrence) and ~1.3 (distance recurrence) associated with a density reduction. There was risk of bias in reporting and study confounding, and uncertainty over the size of the effects. The certainty of the evidence for all recurrence endpoints was very low. Incidence of a secondary primary breast cancer Two studies of 451 women on exemestane, tamoxifen, or unknown endocrine therapy reported risk ratio point estimates of ~0.5 and ~0.6 associated with a density reduction. There was risk of bias in reporting and study confounding, and uncertainty over the effect size. The certainty of the evidence was very low. We were unable to find data regarding the remaining nine outcomes prespecified in the review protocol. Prevention Incidence of invasive breast cancer and ductal carcinoma in situ (DCIS) One study of 507 women without breast cancer who were receiving preventive tamoxifen as part of a randomised controlled trial (51 subsequent breast cancers) reported a risk ratio point estimate of ~0.3 associated with a density reduction. The certainty of the evidence was low. Predictive biomarker findings: One study of a subset of 1065 women from a randomised controlled trial assessed how much the effect of endocrine therapy could be explained by breast density declines in those receiving endocrine therapy. This study evaluated the prevention of invasive breast cancer and DCIS. We found some evidence to support the hypothesis, with a risk ratio interaction point estimate ~0.5. However, the 95% confidence interval included unity, and data were based on 51 women with subsequent breast cancer in the tamoxifen group. The certainty of the evidence was low.

Authors' conclusions: There is low-/very low-certainty evidence to support the hypothesis that breast density change following endocrine therapy is a prognostic biomarker for treatment or prevention. Studies suggested a potentially large effect size with tamoxifen, but the evidence was limited. There was less evidence that breast density change following tamoxifen preventive therapy is a predictive biomarker than prognostic biomarker. Evidence for breast density change as a prognostic treatment biomarker was stronger for tamoxifen than aromatase inhibitors. There were no studies reporting mammographic density change following endocrine therapy as a predictive biomarker in the treatment setting, nor aromatase inhibitor therapy as a prognostic or predictive biomarker in the preventive setting. Further research is warranted to assess mammographic density as a biomarker for all classes of endocrine therapy and review endpoints.

PubMed Disclaimer

Conflict of interest statement

JC has previously received research funding from AstraZeneca and is a member of the scientific advisory board for Atossa Genetics. JC and AB report royalty payments through Cancer Research UK for use of the Tyrer‐Cuzick breast cancer risk assessment algorithm. EA and MT declare no conflicts of interest.

We planned that if any studies eligible for inclusion in the review were co‐authored by any of the authors of this Cochrane Review, these authors would not be involved in the risk of bias assessment or data extraction of these articles.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias domain for each included study; "+": low risk of bias, "?": moderate risk of bias, "‐": high risk of bias.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD013091

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Cuzick 2011a {published and unpublished data}
    1. Cuzick J, Warwick J, Pinney E, Duffy S, Simon C, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. Journal of the National Cancer Institute 2011;103(9):744-52. - PubMed
Kim 2012 {published data only}
    1. Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Research 2012;14(4):R102. - PMC - PubMed
Knight 2018 {published data only (unpublished sought but not used)}
    1. Knight JA, Blackmore KM, Fan J, Malone KE, John EM, Lynch CF, et al. The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Research 2018;20(1):23. - PMC - PubMed
Ko 2013 {published data only}
    1. Ko KL, Shin IS, You JY, Jung SY, Ro J, Lee ES. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients. Breast Cancer Research and Treatment 2013;142(3):559-67. - PubMed
Li 2013 {published data only}
    1. Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. Journal of Clinical Oncology 2013;31(18):2249-56. - PMC - PubMed
Nyante 2015 {published data only}
    1. Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, et al. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. Journal of the National Cancer Institute 2015;107(3):dju425. - PMC - PubMed
Sandberg 2013 {published data only}
    1. Sandberg ME, Li J, Hall P, Hartman M, dos Santos Silva I, Humphreys K, et al. Change of mammographic density predicts the risk of contralateral breast cancer - a case-control study. Breast Cancer Research 2013;15(4):R57. - PMC - PubMed
van Nes 2015 {published and unpublished data}
    1. Nes JG, Beex LV, Seynaeve C, Putter H, Sramek A, Lardenoije S, et al. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis. Acta Oncologica 2015;54(3):349-60. - PubMed

References to studies excluded from this review

Andersson 2017 {published data only}
    1. Andersson TM, Crowther MJ, Czene K, Hall P, Humphreys K. Mammographic density reduction as a prognostic marker for postmenopausal breast cancer: results using a joint longitudinal-survival modelling approach. American Journal of Epidemiology 2017;186(9):1065-73. - PMC - PubMed
Atkinson 1999 {published data only}
    1. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiology, Biomarkers & Prevention 1999;8:863–6. - PubMed
Becker 2009 {published data only}
    1. Becker S, Kaaks R. Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk? Recent Results in Cancer Research 2009;181:135-57. - PubMed
Boisserie‐Lacroix 2008 {published data only}
    1. Boisserie-Lacroix M, Lebiez-Michel N, Cavagni P, Bentolila J, Laumonier H, Bouzgarrou M, et al. Hormones and mammographic breast density [Hormones et densité mammaire]. Journal de Radiologie 2008;89(9):1196-203. - PubMed
Boutet 2004 {published data only}
    1. Boutet G, Boisserie-Lacroix M, Trillaud H. Menopausal hormonal therapies: impact on mammographic breast density [Thérapeutiques hormonales de la ménopause: impact sur la densité mammographique]. Journal de Radiologie 2004;85(10 Pt 1):1673-86. - PubMed
Boyd 2001 {published data only}
    1. Boyd NF, Martin LJ, Stone J, Greenberg C, Minkin S, Yaffe MJ. Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention. Current Oncology Reports 2001;3:314–21. - PubMed
Boyd 2011 {published data only}
    1. Boyd NF. Tamoxifen, mammographic density, and breast cancer prevention. Journal of the National Cancer Institute 2011;103(9):704-5. - PubMed
Chlebowski 2003 {published data only}
    1. Chlebowski RT, McTiernan A. Biological significance of interventions that change breast density. Journal of the National Cancer Institute 2003;95(1):4-5. - PubMed
Cosmacini 1993 {published data only}
    1. Cosmacini P, Cassano E, Sacchini V, Coopmans de Yoldi G, Costa A. Chemoprevention of breast cancer by using tamoxifen: radiologic evaluation. Radiology 1993;189(Suppl):245.
Cuzick 2012 {published data only}
    1. Cuzick J. Breast density predicts endocrine treatment outcome in the adjuvant setting. Breast Cancer Research 2012;14(4):109. - PMC - PubMed
Decensi 2004 {published data only}
    1. Decensi A, Bonanni B, Guerrieri GA, Robertson C, Cazzaniga M, Mariette F, et al. A randomized 2x2 biomarker trial of low-dose tamoxifen and fenretinide in postmenopausal women at high-risk for breast cancer. In: American Society of Clinical Oncology Annual Meeting; 2004 June 5–8; New Orleans. Baltimore: Lippincott Williams & Wilkins, 2004:97.
Decensi 2009 {published data only}
    1. Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, et al. Randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. Journal of Clinical Oncology 2009;27(23):3749-56. - PMC - PubMed
Ekpo 2016 {published data only}
    1. Ekpo EU, Brennan PC, Mello-Thoms C, McEntee MF. Relationship between breast density and selective estrogen-receptor modulators, aromatase inhibitors, physical activity, and diet: a systematic review. Integrative Cancer Therapies 2016;15(2):127–44. - PMC - PubMed
Engmann 2017 {published data only}
    1. Engmann NJ, Scott CG, Jensen MR, Ma L, Brandt KR, Mahmoudzadeh AP, et al. Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. Cancer Epidemiology, Biomarkers & Prevention 2017;26(6):930-7. - PMC - PubMed
Eriksson 2018 {published data only}
    1. Eriksson L, He W, Eriksson M, Humphreys K, Bergh J, Hall P, et al. Adjuvant therapy and mammographic density changes in women with breast cancer. JNCI Cancer Spectrum 2018;2(4):pky071. - PMC - PubMed
Fabian 2006 {published data only}
    1. Fabian CJ, Kimler BF. Mammographic density: use in risk assessment and as a biomarker in prevention trials. Journal of Nutrition 2006;136(10):2705S-8S. - PubMed
Fabian 2007 {published data only}
    1. Fabian CJ, Kimler BF. Use of biomarkers for breast cancer risk assessment and prevention. Journal of Steroid Biochemistry and Molecular Biology 2007;106(1-5):31-9. - PubMed
Fabian 2016 {published data only}
    1. Fabian CJ, Kimler BF. Incorporating biomarkers in studies of chemoprevention. Advances in Experimental Medicine and Biology 2016;882:69-94. - PubMed
Ghosh 2010 {published data only}
    1. Ghosh K, Vachon CM. Mammographic breast density, endocrine therapies, and breast cancer risk. Sexuality, Reproduction and Menopause 2010;8(1):34-9.
Kanbayti 2019 {published data only}
    1. Kanbayti IH, Rae WI, McEntee MF, Ekpo EU. Are mammographic density phenotypes associated with breast cancer treatment response and clinical outcomes? A systematic review and meta-analysis. Breast 2019;47:62-76. - PubMed
Kim 2014 {published data only}
    1. Kim JY, Cho N, Jeyanth JX, Kim WH, Lee SH, Gweon HM, et al. Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy. American Journal of Roentgenology 2014;202(4):912-21. - PubMed
Kmietowicz 2013 {published data only}
    1. Kmietowicz Z. Breast density on mammography can help assess response to tamoxifen and predict survival, finds study. BMJ 2013;346:f2645. - PubMed
Macis 2011 {published data only}
    1. Macis D, Gandini S, Guerrieri-Gonzaga A, Harriet J, Serrano D, Cazzaniga M, et al. Associations between a polymorphic locus in the promoter region of the IGFBP-3 gene, circulating IGFs, mammographic breast density and survival in a 2x2 trial of low-dose tamoxifen and fenretinide in premenopausal women. In: 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando (FL). Vol. 71 (8 Suppl). Philadelphia: AACR; Cancer Research, 2011:Abstract number 3671.
Martin 2009 {published data only}
    1. Martin L, Minkin S, Boyd N. Hormone therapy, mammographic density, and breast cancer risk. Maturitas 2009;64(1):20-6. - PubMed
Martin 2016 {published data only}
    1. Martin HL, Yap F, Chung K, Stone J, Redfern A. Mammographic breast-density change as a predictor of outcome in hormone receptor positive breast cancer. Asia-Pacific Journal of Clinical Oncology 2016;12(Suppl 5):72.
Mullooly 2016 {published data only}
    1. Mullooly M, Pfeiffer R, Nyante S, Heckman-Stoddard BM, Perloff M, Jatoi I, et al. Mammographic density as a biosensor of tamoxifen effectiveness in adjuvant endocrine treatment of breast cancer: opportunities and implications. Journal of Clinical Oncology 2016;34(18):2093–7. - PMC - PubMed
Mullooly 2018 {published data only}
    1. Mullooly M, Gierach GL. The potential for mammographic breast density change as a biosensor of adjuvant tamoxifen therapy adherence and response. JNCI Cancer Spectrum 2018;2(4):pky072. - PMC - PubMed
Mullooly 2019 {published data only}
    1. Mullooly M, Nyante SJ, Pfeiffer RM, Cora R, Butcher D, Sternberg L, et al. Involution of breast lobules, mammographic breast density and prognosis among tamoxifen-treated estrogen receptor-positive breast cancer patients. Journal of Clinical Medicine 2019;8:1868. - PMC - PubMed
NCT00066586 {published data only}
    1. NCT00066586. Exemestane in reducing breast density in postmenopausal women at risk for breast cancer. clinicaltrials.gov/ct2/show/NCT00066586 (first received 7 August 2003).
NCT00086749 {published data only}
    1. NCT00086749. Effect of tamoxifen on breast density in premenopausal women with breast cancer or high risk for breast cancer. clinicaltrials.gov/ct2/show/NCT00086749 (first received 12 July 2004).
NCT00114270 {published data only}
    1. NCT00114270. Letrozole with or without zoledronate in treating healthy postmenopausal women with high breast density. clinicaltrials.gov/ct2/show/NCT00114270 (first received 14 June 2005).
NCT00238316 {published data only}
    1. NCT00238316. Letrozole in preventing breast cancer in postmenopausal women who are at increased risk for breast cancer due to high breast density. clinicaltrials.gov/ct2/show/NCT00238316 (first received 13 October 2005).
NCT00316836 {published data only}
    1. NCT00316836. Breast density, hormone levels, and anticancer drug levels in women with invasive breast cancer who are receiving exemestane or anastrozole. clinicaltrials.gov/ct2/show/NCT00316836 (first received 21 April 2006).
NCT00445445 {published data only}
    1. NCT00445445. Changes in breast density and breast cancer risk in women with breast cancer and in healthy women. clinicaltrials.gov/ct2/show/NCT00445445 (first received 9 March 2007).
NCT00516698 {published data only}
    1. NCT00516698. Changes in breast density and blood hormone levels in postmenopausal women receiving anastrozole or exemestane for breast cancer. clinicaltrials.gov/ct2/show/NCT00516698 (first received 15 August 2007).
NCT01765049 {published data only}
    1. NCT01765049. Breast density change predicting response to adjuvant aromatase inhibitor (DEAR). clinicaltrials.gov/ct2/show/NCT01765049 (first received 10 January 2013).
NCT01773551 {published data only}
    1. NCT01773551. Development of a quantitative tissue optical index of breast density for prediction of hormone therapy response. clinicaltrials.gov/ct2/show/NCT01773551 (first received 23 January 2013).
Ozhand 2013 {published data only}
    1. Ozhand A, McKean-Cowdin R, Bernstein L, Ballard-Babash R, McTiernan A, Baumgartner KB. Short term reduction in mammographic density predicts survival in breast cancer. In: 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Vol. 73 (8 Suppl). Philadelphia: AACR; Cancer Research, 2013:Abstract number 2286.
Redfern 2016a {published data only}
    1. Redfern A. Breast density change: toward tailoring of adjuvant endocrine therapy. Asia-Pacific Journal of Clinical Oncology 2016;12(Suppl 5):100.
Redfern 2016b {published data only}
    1. Redfern AD, Martin HL, Stone J, Davidson JA, Yap F, Chung K. Mammographic breast density as a predictor of hormone receptor positive breast cancer recurrence: a single centre longitudinal analysis. In: 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2015 Dec 8-12; San Antonio (TX). Vol. 76 (4 Suppl). Philadelphia: AACR; Cancer Research, 2016:Abstract number PD1-06.
Shawky 2017 {published data only}
    1. Shawky MS, Martin H, Hugo HJ, Lloyd T, Britt KL, Redfern A, et al. Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies. Oncotarget 2017;8(3):5578-91. - PMC - PubMed
Ursin 1996 {published data only}
    1. Ursin G, Pike MC, Spicer DV, Porrath SA, Reitherman RW. Can mammographic densities predict effects of tamoxifen on the breast? Journal of the National Cancer Institute 1996;88(2):128-9. - PubMed
Vachon 2013a {published data only}
    1. Vachon CM, Ghosh K, Brandt KR. Mammographic density: potential as a risk factor and surrogate marker in the clinical setting. Current Breast Cancer Reports 2013;5(3):183-93.
Vachon 2013b {published data only}
    1. Vachon C, Suman V, Brandt K, Kosel M, Buzdar A, Olson J, et al. Mammographic breast density response to aromatase inhibition. Clinical Cancer Research 2013;19(8):2144-53. - PMC - PubMed
Whitman 2000 {published data only}
    1. Whitman GJ, Stelling CB, Sunku K. Mammographic changes by endocrine therapy. Seminars in Breast Disease 2000;3(2):70-80.

Additional references

Altman 1998
    1. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Research and Treatment 1998;52(1-3):289-303. - PubMed
Altman 2001
    1. Altman DG. Systematic reviews in health care: systematic reviews of evaluations of prognostic variables. BMJ 2001;323(7306):224-8. - PMC - PubMed
Altman 2012
    1. Altman D, McShane L, Sauerbrei W, Taube S. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLOS Medicine 2012;9(5):e1001216. - PMC - PubMed
Assi 2011
    1. Assi V, Warwick J, Cuzick J, Duffy S. Clinical and epidemiological issues in mammographic density. Nature Reviews Clinical Oncology 2011;9(1):33-40. - PubMed
Bland 1999
    1. Bland JM, Altman DG. Measuring agreement in method comparison studies. Statistical Methods in Medical Research 1999;8(2):135-60. - PubMed
Boyd 1998
    1. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiology and Prevention Biomarkers 1998;7(12):1133-44. - PubMed
Boyd 2006
    1. Boyd N, Martin L, Li Q, Sun L, Chiarelli A, Hislop G, et al. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiology, Biomarkers & Prevention 2006;15(5):961-6. - PubMed
Byng 1994
    1. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Physics in Medicine and Biology 1994;39(10):1629-38. - PubMed
Byrne 2017
    1. Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, et al. Mammographic density change with estrogen and progestin therapy and breast cancer risk. Journal of the National Cancer Institute 2017;109(9):1-7. - PMC - PubMed
CGHFBC 2019
    1. Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC). Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394(10204):1159-68. - PMC - PubMed
Covidence [Computer program]
    1. Veritas Health Innovation Covidence. Version accessed 28 June 2018. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.
Cuzick 2004
    1. Cuzick J, Warwick J, Pinney E, Warren R, Duffy S. Tamoxifen and breast density in women at increased risk of breast cancer. Journal of the National Cancer Institute 2004;96(8):621-8. - PubMed
Cuzick 2011b
    1. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. Journal of Clinical Oncology 2011;29(32):4273-8. - PubMed
Cuzick 2013
    1. Cuzick J, Sestak I, Bonanni B, Costantino J, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381(9880):1827-34. - PMC - PubMed
Cuzick 2014
    1. Cuzick J, Sestak I, Forbes J, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;383(9922):1041-8. - PubMed
Cuzick 2015
    1. Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncology 2015;16(1):67-75. - PMC - PubMed
D'Orsi 2013
    1. D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA. ACR BI-RADS Atlas: Breast Imaging Reporting and Data System. ACR, American College of Radiology, 2013.
Davies 2011
    1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al, Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378(9793):771-84. - PMC - PubMed
EBCTCG 1998
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451-67. - PubMed
EBCTCG 2015
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386(10001):1341-52. - PubMed
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. - PMC - PubMed
Ferlay 2013
    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. globocan.iarc.fr (accessed 1 September 2016).
Gail 1989
    1. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute 1989;81(24):1879-86. - PubMed
Google Scholar
    1. Google. Google Scholar. scholar.google.com (accessed 5 July 2021).
Google Translate
    1. Google. Google Translate. translate.google.com (accessed 5 July 2021).
Goss 2011
    1. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine 2011;364:2381–91. - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed 26 June 2018. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Gram 1997
    1. Gram IT, Funkhouser E, Tabár L. The Tabár classification of mammographic parenchymal patterns. European Journal of Radiology 1997;24(2):131-6. - PubMed
Harris 2007
    1. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology 2007;25(33):5287-312. - PubMed
Harvey 1997
    1. Harvey J, Herman C, Pinkerton J. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. Journal of the National Cancer Institute 1997;89(21):1623-5. - PubMed
Hayden 2006
    1. Hayden J, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Annals of Internal Medicine 2006;144(6):427-37. - PubMed
Hayden 2013
    1. Hayden JA, Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Annals of Internal Medicine 2013;158(4):280-6. - PubMed
Highnam 2010
    1. Highnam R, Brady M, Yaffe MJ, Karssemeijer N, Harvey J. Robust Breast Composition Measurement - Volpara™. In: Martí J, Oliver A, Freixenet J, Martí R, editors(s). Digital Mammography. Vol. 6136. Berlin: Springer, 2010:342-9.
Hingorani 2013
    1. Hingorani A, Windt D, Riley R, Abrams K, Moons KG, Steyerberg EW, et al. Prognosis research strategy (PROGRESS) 4: Stratified medicine research. BMJ 2013;346:e5793. - PMC - PubMed
Huo 2014
    1. Huo CW, Chew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL, et al. Mammographic density - a review on the current understanding of its association with breast cancer. Breast Cancer Research and Treatment 2014;144(3):479-502. - PubMed
Jordan 2007
    1. Jordan C. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 2007;72(13):829-42. - PMC - PubMed
Komm 2014
    1. Komm B, Mirkin S. An overview of current and emerging SERMs. Journal of Steroid Biochemistry and Molecular Biology 2014;143:207-22. - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. - PMC - PubMed
McCormack 2006
    1. McCormack V, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiology, Biomarkers & Prevention 2006;15(6):1159-69. - PubMed
McShane 2005
    1. McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G. Reporting recommendations for tumor marker prognostic studies. Journal of Clinical Oncology 2005;23(36):9067-72. - PubMed
McTiernan 2005
    1. McTiernan A, Martin C, Peck J, Aragaki A, Chlebowski R, Pisano E, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. Journal of the National Cancer Institute 2005;97(18):1366-76. - PubMed
PubMed
    1. National Center for Biotechnology Information. PubMed. pubmed.ncbi.nlm.nih.gov (accessed 5 July 2021).
Review Manager 2020 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.
Riley 2009
    1. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis and beyond. British Journal of Cancer 2009;100(8):1219-29. - PMC - PubMed
Riley 2013
    1. Riley R, Hayden J, Steyerberg E, Moons KG, Abrams K, Kyzas PA, et al. Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. PLOS Medicine 2013;10(2):e1001380. - PMC - PubMed
Rutter 2001
    1. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285(2):171-6. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glaziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Schünemann 2013
    1. Schünemann H, Brozek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.
Sterne 2016
    1. Sterne J, Hernán M, Reeves B, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. - PMC - PubMed
Tice 2008
    1. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Annals of Internal Medicine 2008;148(5):337-47. - PMC - PubMed
Tyrer 2004
    1. Tyrer J, Duffy S, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine 2004;23(7):1111-30. - PubMed
Visvanathan 2013
    1. Visvanathan K, Hurley P, Bantug E, Brown P, Col N, Cuzick J, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology 2013;31(23):2942-62. - PubMed
Wolfe 1976
    1. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. American Journal of Roentgenology 1976;126(6):1130-7. - PubMed

References to other published versions of this review

Atakpa 2018
    1. Atakpa EC, Thorat MA, Cuzick J, Brentnall AR. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. Cochrane Database of Systematic Reviews 2018, Issue 8. Art. No: CD013091. [DOI: 10.1002/14651858.CD013091] - DOI - PMC - PubMed

Publication types